Cargando…
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
Knowledge of the genomic landscape of chronic lymphocytic leukemia (CLL) grows increasingly detailed, providing challenges in contextualizing the accumulated information. To define the underlying networks, we here perform a multi-platform molecular characterization. We identify major subgroups chara...
Autores principales: | Bloehdorn, Johannes, Braun, Andrejs, Taylor-Weiner, Amaro, Jebaraj, Billy Michael Chelliah, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz, Scheffold, Annika, Johnston, Harvey E., Yeh, Ru-Fang, Klymenko, Tetyana, Tausch, Eugen, Eichhorst, Barbara, Bullinger, Lars, Fischer, Kirsten, Weisser, Martin, Robak, Tadeusz, Schneider, Christof, Gribben, John, Dahal, Lekh N., Carter, Mathew J., Elemento, Olivier, Landau, Dan A., Neuberg, Donna S., Cragg, Mark S., Benner, Axel, Hallek, Michael, Wu, Catherine J., Döhner, Hartmut, Stilgenbauer, Stephan, Mertens, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438057/ https://www.ncbi.nlm.nih.gov/pubmed/34518531 http://dx.doi.org/10.1038/s41467-021-25403-y |
Ejemplares similares
-
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients
por: Bloehdorn, Johannes, et al.
Publicado: (2021) -
Lamin B1 regulates somatic mutations and progression of B-cell malignancies
por: Klymenko, T, et al.
Publicado: (2018) -
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019) -
Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
por: Edelmann, Jennifer, et al.
Publicado: (2021) -
P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)